t r a c t
Five cattle and five sheep that had never been exposed to bluetongue virus (BTV), as well as ten animals that had been experimentally infected with BTV-8, were inoculated with BTV-1. Previous exposure to BTV-8 did not prevent a second infection with another serotype.
After the experiment, the BTV-1 preparation was found to be contaminated with BTV-15. The inoculum and blood samples taken during the experiment were analysed by serotype-specific real-time RT-PCR. There was 100-fold less BTV-15 than BTV-1 in the inoculum. Unexpectedly, BTV-15 dominated the infection in cattle that had previously been exposed to BTV-8. In sheep of both groups, on the other hand, BTV-1 prevailed over the contaminant.
Regardless of the outcome, the incident demonstrates the need for a thorough contamination screening of virus preparations. For this purpose, two type-specific RT-PCR primer sets for each of the 24 established BTV serotypes as well as Toggenburg Orbivirus were designed.
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There are at least 24 serotypes of Bluetongue virus (BTV), an arthropod-borne reovirus that affects domestic and wild ruminants worldwide. In many research laboratories, different strains and serotypes of BTV as well as related viruses are handled at the same time. Despite best efforts, contamination does occur and can have far-reaching consequences.
In the present study, six Holstein Friesian cattle and four German Blackhead Mutton sheep had been experimentally infected with BTV-8 (isolated in Germany in 2007). Six weeks later, they were challenged with a French isolate of BTV-1, kindly provided by ANSES. To investigate the cross-protective influence of the previous exposure to BTV-8, five BTV-naïve cattle and sheep were also inoculated with the same BTV-1 preparation at the same time. All animals were subcutaneously injected with Vero cell culture supernatant that contained 10 6.3 TCID 50 of BTV. Since the BTV-1 isolate had originally been intended for PCR validation only, it had not undergone the usual checks for a challenge inoculum at the sending laboratory. In fact, ANSES had not certified it as pure. For the experiment, the received material was passaged once at the FLI. Real-time RT-PCR analysis [1] of the passaged material confirmed that it contained a large amount of BTV-1, but other serotypes were not tested for. It was later revealed that the BTV-1 isolate had been contaminated with BTV-15. This contamination was only discovered when samples from the animal experiment were sent to the Istituto G. Caporale for serum neutralization tests. After neutralizing antibodies against BTV-15 had been found in serum samples, blood from the animals and the supernatant used for infection were examined by a serotypespecific RT-PCR amplifying a 413 bp fragment of BTV-15 genome segment 2 (see Table 1 ). Since these were also positive, the inoculum and all samples from the animal experiment were re-tested using a modified CY5-labeled BTV-1 assay [1] and a newly designed BTV-15 assay (see Table 1 ) in a single-tube duplex real-time RT-PCR. Serial dilutions of BTV-1 and BTV-15 RNA preparations whose copy numbers had been determined by an externally calibrated pan-BTV S5 assay [2] were used for absolute quantification. The VP2 gene sequence of the contaminant was obtained and deposited in GenBank (accession number JF343006). BLAST analysis 2 revealed only 96% identity to the VP2 gene of the South African reference strain "RSArrrr/15", the only available BTV-15 VP2 gene sequence in the database. The BTV-1 strain used in this study had originally been isolated in France from a sheep with clinical signs of bluetongue. There is no indication that BTV-15 has ever circulated in Europe. An Israeli strain of BTV-15, however, had been handled at the sending laboratory at the same time as the BTV-1 isolate. This is suspected as the origin of the contamination, but no further attempt was made to confirm that.
In the real-time RT-PCR, the inoculum was strongly positive for BTV-1 RNA with a mean C t value of 17.1 (3.4 × 10 9 segment 2 RNA copies per ml), but also contained an about 100-fold lower amount of BTV-15 (C t 24.6; 3.6 × 10 7 copies per ml). Surprisingly, this difference was not uniformly reflected in the course of infection observed in the experiment.
The outcome was very different between the two host species (see Fig. 1 ). High amounts of BTV-1 RNA were detected in all sheep, regardless of their BTV exposure history. Two of the four previously BTV-8 infected sheep did not show any BTV-15 replication at all, and it was much reduced in a third. In naïve sheep, BTV-15 replication on average was reduced 100-fold compared to BTV-1.
In three of the six cattle previously infected with BTV-8, on the other hand, no BTV-1 replication was detected at all, and it was about 100-fold reduced in a fourth. Interestingly, previously infected cattle that were negative for BTV-1 were highly positive for BTV-15. Finally, in samples from naïve cattle, BTV-1 and BTV-15 RNA were detected in roughly equal amounts.
In summary, even though there was over 100-fold less BTV-15 in the inoculum, this serotype dominated the infection in cattle that had previously been exposed to BTV-8. In sheep of both groups, 2 NCBI Basic Local Alignment Search Tool, http://blast.ncbi.nlm.nih.gov.
on the other hand, BTV-1 prevailed over the contaminant. A BTV infection with a single serotype generally does not induce immunity to other serotypes [3] , and previous BTV-8 exposure did not prevent infection with another BTV serotype in either species in this experiment.
The observed differences in replication suggest that the contaminating strain of BTV-15 is particularly well adapted to cattle, considering it easily made up for the over 100-fold lower inoculated dose. It is unclear whether the dominance of BTV-1 in sheep is simply due to interference between the viruses (where the lower dose could place BTV-15 at a competitive disadvantage), or if BTV-1 in turn is better suited to replication in sheep. Jeggo et al. have previously proposed a mechanism for interference based on cross-reactive cytotoxic T-lymphocytes [4] , and another study of mixed BTV infection of sheep has also reported differences in growth behavior between virus strains [5] . It is well established that the clinical manifestation of BTV infection varies between host species as well as virus strains [6] , but little is known about the species preference of individual BTV strains, if indeed there is any.
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